机构：[1]School of New Energy and Materials, Southwest Petroleum University, Chengdu 610500, China.[2]Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.[3]Department of Ultrasound, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China School of Medicine, Chengdu 610500, China.四川省人民医院[4]Department of Ophthalmology, The Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
Chemodynamic therapy (CDT) that involves the use of Fenton catalysts to convert endogenous hydrogen peroxide (H2O2) to hydroxyl radicals (·OH) constitutes a promising strategy for cancer therapy; however, insufficient endogenous H2O2 and glutathione (GSH) overexpression render its efficiency unsatisfactory. Herein, we present an intelligent nanocatalyst that comprises copper peroxide nanodots and DOX-loaded mesoporous silica nanoparticles (MSNs) (DOX@MSN@CuO2) and can self-supply exogenous H2O2 and respond to specific tumor microenvironments (TME). Following endocytosis into tumor cells, DOX@MSN@CuO2 initially decomposes into Cu2+ and exogenous H2O2 in the weakly acidic TME. Subsequently, Cu2+ reacts with high GSH concentrations, thereby inducing GSH depletion and reducing Cu2+ to Cu+ Next, the generated Cu+ undergoes Fenton-like reactions with exogenous H2O2 to accelerate toxic ·OH production, which exhibits a rapid reaction rate and is responsible for tumor cell apoptosis, thereby enhancing CDT. Furthermore, the successful delivery of DOX from the MSNs achieves chemotherapy and CDT integration. Thus, this excellent strategy can resolve the problem of insufficient CDT efficacy due to limited H2O2 and GSH overexpression. Integrating H2O2 self-supply and GSH deletion enhances CDT, and DOX-induced chemotherapy endows DOX@MSN@CuO2 with effective tumor growth-inhibiting properties alongside minimal side effects in vivo.
基金：
This work was financially supported by the National Key
Research and Development Program of China
(2019YFA0705803), the National Natural Science Foundation
of China Youth Fund (51803174), the Youth Innovation
Promotion Association CAS (2020190) and the Foundation of
Sichuan Engineering Technology Research Center of Basalt
Fiber Composites Development and Application of Southwest
Petroleum University (2022SCXWYXWFC002).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|2 区医学
小类|2 区药学3 区医学：研究与实验
最新[2023]版：
大类|2 区医学
小类|2 区药学3 区医学：研究与实验
JCR分区：
出版当年[2023]版：
Q1PHARMACOLOGY & PHARMACYQ2MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q1PHARMACOLOGY & PHARMACYQ2MEDICINE, RESEARCH & EXPERIMENTAL
第一作者机构：[1]School of New Energy and Materials, Southwest Petroleum University, Chengdu 610500, China.[*1]School of New Energy and Materials, Southwest Petroleum University, Chengdu 610500, China
通讯作者：
通讯机构：[1]School of New Energy and Materials, Southwest Petroleum University, Chengdu 610500, China.[2]Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.[4]Department of Ophthalmology, The Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.[*1]School of New Energy and Materials, Southwest Petroleum University, Chengdu 610500, China[*2]Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China[*3]Department of Ophthalmology, The Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China
推荐引用方式(GB/T 7714)：
Tang Zhaomin,Jiang Shuting,Tang Wanlan,et al.H2O2 Self-Supplying and GSH-Depleting Nanocatalyst for Copper Metabolism-Based Synergistic Chemodynamic Therapy and Chemotherapy[J].MOLECULAR PHARMACEUTICS.2023,20(3):1717-1728.doi:10.1021/acs.molpharmaceut.2c00937.
APA：
Tang Zhaomin,Jiang Shuting,Tang Wanlan,He Qian,Wei Huangzhao...&Zhang Hui.(2023).H2O2 Self-Supplying and GSH-Depleting Nanocatalyst for Copper Metabolism-Based Synergistic Chemodynamic Therapy and Chemotherapy.MOLECULAR PHARMACEUTICS,20,(3)
MLA：
Tang Zhaomin,et al."H2O2 Self-Supplying and GSH-Depleting Nanocatalyst for Copper Metabolism-Based Synergistic Chemodynamic Therapy and Chemotherapy".MOLECULAR PHARMACEUTICS 20..3(2023):1717-1728
